HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
BA3011 for advanced solid tumors
This study is now recruiting.
This study involves taking a study drug called BA3011. The overall goal of this study is to see is BA3011is a possible treatment for patients with sarcoma.
Who Do I Contact?
If you are interested in participating in the study or want to learn more please contact our study team at cancertrials [at] chop.edu or 267-425-5544.
Eligibility & Criteria
The purpose of this study is to evaluate the safety and tolerability in the study drug, BA3011. This study will enroll patients 12 years of age and older that have been diagnosed with advanced sarcoma that hasn't responded to other treatments. The overall goal of this study is to see if BA3011 is a possible treatment for patients with sarcoma. Subjects will receive BA3011 either alone or in combination with Nivolumab. Both are administered via IV infusion. Study visits include the following assessments: blood draws, electrocardiograms (ECGs), and tissue collection (if a tumor biopsy is performed as part of regular clinical care). Reimbursement for travel may be provided.